{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-023509","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.204000+00:00","generated_at":"2026-06-05T05:26:05.955529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biodesix Q4 revenue $14.7M (+53% YoY); guides FY2024 revenue $65-$68M","bullets":["Full-year 2023 revenue $49.1M, +28% YoY; Lung Diagnostic test volume up 65%.","Q4 gross margin 77% vs 66% a year ago; net loss improved 55% to $9.1M.","FY2023 Adjusted EBITDA loss $32.7M, improved 24% YoY.","Cash $26.3M at Dec 31, 2023; drew $10M second tranche from Perceptive term loan.","FY2024 revenue guidance $65-$68M, representing 32%-39% YoY growth."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-023509","json":"https://secwatch.observer/filing/0000950170-24-023509.json","markdown":"https://secwatch.observer/filing/0000950170-24-023509.md","text":"https://secwatch.observer/filing/0000950170-24-023509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000095017024023509/0000950170-24-023509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000095017024023509/bdsx-20240301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:26:05.955529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e99c3947eedc2d127cabce696ea56c084952f687","claim":"BIODESIX INC reported the fourth quarter and year ended December 31, 2023 results: revenue $14.7 million and $49.1 million for the fourth quarter and fiscal 2023, respectively, net income Net loss of $9.1 million and $52.1 million for the fourth quarter and fiscal 2023, respectively. Guidance reaffirmed.","evidence_excerpt":"Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the fourth quarter and year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439725/000095017024023509/0000950170-24-023509-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$14.7 million and $49.1 million for the fourth quarter and fiscal 2023, respectively"},{"label":"Net income","value":"Net loss of $9.1 million and $52.1 million for the fourth quarter and fiscal 2023, respectively"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}